Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ana Sofía Leal Bramasco"'
Autor:
David Vega‐Morales, Lorena Pérez‐Barbosa, Luis Francisco Vega‐Sevilla, Jorge Antonio Esquivel‐Valerio, Luis Eduardo Ramírez‐Monterrubio, Karina I Gonzalez‐Torres, Ana Sofía Leal‐Bramasco, Cesar V Elizondo‐Solis, Andres Mendiola‐Jimenez, Mario Alberto Garza‐Elizondo, Dionicio Ángel Galarza‐Delgado
Publikováno v:
International Journal of Immunogenetics. 50:19-23
Rheumatoid arthritis (RA) affects approximately 1.5% of the population worldwide and 0.5-3.3% of the Mexican population. The presence of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and anti-carbamylated protein (anti-CarP) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::920c6909603190c15bae55c0ff731dc3
https://doi.org/10.1111/iji.12608
https://doi.org/10.1111/iji.12608
Autor:
Rodolfo Uriarte-Botello, D. Á. Galarza-Delgado, Griselda Serna-Peña, César V. Elizondo-Solis, Mario Alberto Garza-Elizondo, Miguel Ángel Villarreal-Alarcón, R. Pineda-Sic, L. Santoyo-Fexas, Ana Sofía Leal-Bramasco, Octavio Ilizaliturri-Guerra
Publikováno v:
Rheumatology international. 40(10)
Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by multi-organ symptomatology. 16% of the patients with autoimmune thrombocytopenia have SLE and are associated with high mortality. Intravenous methylprednisolone or high-dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfc666e91c20c28e56c68ac587a792fd
https://pubmed.ncbi.nlm.nih.gov/32797277
https://pubmed.ncbi.nlm.nih.gov/32797277
Autor:
Jorge Antonio Esquivel Valerio, Luis Eduardo Ramírez Monterrubio, David Vega Morales, Dionicio Ángel Galarza Delgado, C. V. Solis, Ana Sofía Leal Bramasco, Lorena Pérez Barbosa, Mario Alberto Garza Elizondo, Karina Itzel González Márquez
Publikováno v:
Abstracts Accepted for Publication.
Background Rheumatoid arthritis (RA) affects approximately 1.5% of the population worldwide and 0.5-3.3% of the Mexican population1. Anti-carbamylated proteins (anti-CarP) antibodies are identified in RA patients with a prevalence up to 44%2, early a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c65da38dd79b480c32e2a45d3ec0b9e
https://doi.org/10.1136/annrheumdis-2019-eular.1452
https://doi.org/10.1136/annrheumdis-2019-eular.1452